A Multicenter, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy and Safety of Actonel After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Latest Information Update: 18 Dec 2024
Price :
$35 *
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Dong-A ST
- 16 Dec 2024 Planned End Date changed from 1 Feb 2025 to 1 Jul 2025.
- 16 Dec 2024 Planned primary completion date changed from 1 Feb 2025 to 1 Jul 2025.
- 16 Dec 2024 Status changed from recruiting to active, no longer recruiting.